In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

The race to develop oral obesity drugs is heating up. Eli Lilly (LLY) and Novo Nordisk (NVO), makers of the highly popular ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

She’s been taking the oral, non-injectable medicine ... Lifestyle changes and weight loss drugs Losing weight can lower a person with obesity’s risk of heart disease and other chronic ...

We’re not making any changes to our DKK 600/$86 fair value estimate for Novo Nordisk following somewhat disappointing early data for a novel oral obesity drug candidate, CB1-targeting monlunabant.

The company is also preparing for the potential market introduction of orforglipron, an oral obesity drug, which is expected to further alleviate capacity constraints. The analyst pointed out that ...

Obesity is a major global health problem, increasing the risk of many serious diseases like heart disease, diabetes, and some ...

The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

Biomed Industries, Inc- logo NA-931 for weight loss Biomed pipeline Biomed Industries, Inc. Announces Positive Phase I R ...

The race to develop oral obesity drugs is heating up. Eli Lilly (LLY) and Novo Nordisk (NVO), makers of the highly popular injectable GLP-1 class of weight loss drugs, as well as potential new ...

This expansion is seen as a strategic move to address the complex challenges of forecasting supply and backlog for its drug Zepbound in the short term. The company is also preparing for the potential ...